| VACCINES | ||||
| # | Trade Name | Generic | Dose | Marketing Authorization Holder |
| 1 | Corona Vac | SARS-COV-2 (vero cell) Incativated | Unit/0.5ml | Sinovac Life Science-China |
| 2 | Sars cov-2 vaccine (vero cell) inactivated | SARS-COV-2 (vero cell) Incativated | 0.5ml | Beijing Institute of Biological Products Co.,Ltd. Sinopharm CNBG, China |
| 3 | Covid-19 vaccine (vero cell) inactivated | SARS-COV-2 (vero cell) Incativated | 0.5ml | The holding company for biological products and vaccines - Egyptian Company for Production of Vaccines , Sera and Drugs( EGYVAC ) |
| 4 | Vaxzevira (covid- 19 vaccine AstraZeneca) | ChAdox1 nCoV-19 Corona Virus Vaccine (Recombinant) | 0.5ml | Astrazeneca-Oxford |
| 5 | Gam-COVID-vac (Sputnik-V) | SARS-COV-2 adenoviral vector vaccine consists of 2 Component administrated separately within a recommended time interval, component I: serotype 26 recombinant adenovirus particles containing SARS-CoV-2 protein S gene (1.0±.05 )X 10^11 particles and component II: serotype 5 recombinant adenovirus particles containing SARS-CoV-2 protein S gene (1.0±.05 )X 10^11 particles | 0.5ml | FSBI Gamalaya RCEM of Ministry of Health-Russia |
| 6 | Comirnaty | Tozinameran, 1 Novel COVID-19 mRNA vaccine (Nucleoside Modified) | 0.3ml | Pfizer BioNTech |
| 7 | Spikevax (COVID-19 mRNA -1273 Vaccine) | 100mcg of mRNA (embedded in SM-102 lipid nanoparticles | 0.5ml | Moderna |
| 8 | Sputnik -L | SARS-COV-2 adenoviral vector vaccine consists of serotype 26 recombinant adenovirus particles containing SARS-CoV-2 protein S gene (1.0±.05 )X 10^11 particles | 0.5ml | FSBI Gamalaya RCEM of Ministry of Health-Russia |
| 9 | Covid-19 Vaccine JANSSEN | Recombinant adenoviral vector that contains the sequence that encodes the spike protein (S) of the SARS-CoV-2 virus | 0.5ml | Janssen |
| MONOCLONAL ANTIBODIES | ||||
| # | Trade Name | Generic | Marketing Authorization Holder | |
| 1 | Sotrovimab | 550mg sotrovimab | GlaxoSmithKline | |
| 2 | REGN-COV2 | Casirivimab 120 mg/mL. Imdevimab 120 mg/mL. |
Roche | |